This is a synthetic peptide designed for use in combination with anti-CRADD Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
CRADD
Reaktivität: Human, Maus, Ratte
Wirt: Synthetic
BP
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
CRADD
(CASP2 and RIPK1 Domain Containing Adaptor with Death Domain (CRADD))
Synonyme
cradd Peptide, MGC89035 Peptide, zgc:101717 Peptide, CRADD Peptide, DKFZp468A2219 Peptide, LOC100226369 Peptide, raidd Peptide, MGC78788 Peptide, MRT34 Peptide, RAIDD Peptide, CASP2 and RIPK1 domain containing adaptor with death domain Peptide, CASP2 and RIPK1 domain containing adaptor with death, gene 1 Peptide, CASP2 and RIPK1 domain containing adaptor with death, gene 2 S homeolog Peptide, CRADD Peptide, cradd.1 Peptide, cradd Peptide, cradd.2.S Peptide, Cradd Peptide
Hintergrund
The protein encoded by this gene is a death domain (CARD/DD)-containing protein and has been shown to induce cell apoptosis. Through its CARD domain, this protein interacts with, and thus recruits, caspase 2/ICH1 to the cell death signal transduction complex that includes tumor necrosis factor receptor 1 (TNFR1A), RIPK1/RIP kinase, and numbers of other CARD domain-containing proteins.